Clinically reviewed by Dr. Hemal V. Mehta, MD and Kate Sherman, PA-C, Vita Nova Stem Cell Professionals
If a surgeon has told you that your knee needs replacement and you are not ready to say yes, you are asking the right question. Knee replacement works. For end-stage osteoarthritis, severe instability, or failed cartilage, it is sometimes the only path that restores function. But it is also a major operation, irreversible, with a recovery measured in months and an implant lifespan that matters most for patients still in their fifties and sixties.
Knee pain therapy without surgery covers more ground than most patients realize. Physical therapy, cortisone, hyaluronic acid, PRP, and regenerative cell-based approaches each work through different mechanisms, address different problems, and carry different timelines. Understanding what each option actually does, where it works, and where it falls short is what lets you make a decision you will not second-guess later. The map matters. What you try first shapes what comes next, and what makes someone a candidate for regenerative care is a separate question from what works in the first place.
Why Standard Care Often Stalls
Most knee patients follow the same sequence: anti-inflammatories, physical therapy, cortisone, hyaluronic acid, then a referral to an orthopedic surgeon. Each step is clinically reasonable. But for a significant number of patients, none of them resolves the underlying problem.
The reason depends on the condition. Cartilage loss in osteoarthritis is structural; physical therapy strengthens the muscles around the joint but does not rebuild what is gone. Cortisone reduces inflammation quickly but does not change the trajectory of the disease. Hyaluronic acid lubricates but does not repair. Each option addresses a piece of the picture without addressing the underlying degeneration.
Standard care manages symptoms. When tissue damage is what is driving the pain, symptom management buys time but does not close the gap. That is where the map of non-surgical options becomes more important.
Physical Therapy
Physical therapy strengthens the quadriceps, hamstrings, and gluteal muscles that support the knee. Better muscle control reduces load on the joint and improves function. For early osteoarthritis, post-injury rehabilitation, and patellofemoral pain, a structured program often produces meaningful improvement.
Where it falls short: when the underlying tissue is too degenerated for muscle work alone to compensate. A patient with moderate-to-advanced osteoarthritis or significant meniscal damage may plateau in PT because the structural problem remains.
Physical therapy is rarely wasted even when it does not resolve the primary pain. It builds the muscle support that makes every other intervention more effective and every surgical recovery faster.
Corticosteroid Injections
Cortisone reduces inflammation quickly. For acute flares it provides real, often immediate relief that can last weeks to months. It is widely available, inexpensive, and covered by most insurance.
The complication is what cortisone does over time. A 2017 randomized controlled trial published in JAMA followed 140 knee osteoarthritis patients receiving either triamcinolone or saline injections every three months for two years. The triamcinolone group showed greater cartilage volume loss than the saline group, with no significant difference in pain reduction. The authors concluded the findings did not support this treatment for symptomatic knee osteoarthritis. Most orthopedic providers now recommend limiting cortisone injections to two or three per joint per year.
Cortisone is a time-buying tool. Useful when the goal is to reduce acute pain while pursuing other approaches. Less useful as a primary long-term strategy when the underlying problem is structural cartilage loss.
Hyaluronic Acid Injections
Hyaluronic acid injections add lubrication to the joint. FDA-approved for knee osteoarthritis specifically, they are one of the few intra-articular options with that designation. For patients whose primary complaint is stiffness and grinding rather than acute inflammation, they may provide months of symptom relief.
The mechanism is not regenerative. Hyaluronic acid does not repair cartilage. It reduces friction in the joint and may carry a modest anti-inflammatory effect. A reasonable middle step for patients who have not responded to cortisone but are not yet pursuing more advanced approaches.
Platelet-Rich Plasma (PRP) Therapy
PRP uses your own blood, processed to concentrate platelets, then injected into the affected knee under image guidance. Platelets carry growth factors that signal tissue repair and reduce inflammation. Because PRP is derived from your own blood, there is no rejection risk.
Research on PRP for knee osteoarthritis is among the strongest evidence base in regenerative medicine. A 2025 meta-analysis in the American Journal of Sports Medicine pooled 18 randomized controlled trials covering 1,995 patients. High-platelet PRP formulations showed statistically and clinically significant improvements in pain and function compared to placebo at 3, 6, and 12 months. Low-platelet PRP did not produce the same sustained benefit. This distinction matters for patients evaluating providers, because not all PRP is the same. Preparation method, platelet concentration, and injection technique each influence outcome. When evaluating a PRP provider, asking how their PRP is prepared and what platelet concentration they target is a reasonable question.
A separate 2024 meta-analysis in the same journal looked at PRP from a different angle, comparing it to alternative non-operative treatments rather than placebo. It found PRP outperformed hyaluronic acid for pain relief and reduced the need for additional intervention.
PRP does not produce the same result for every patient. It is most effective for mild-to-moderate osteoarthritis (Kellgren-Lawrence grades I-III). Patients with bone-on-bone end-stage disease are less likely to see meaningful benefit and may be better served by surgical evaluation.
Regenerative Cell-Based Therapy
Cell-based approaches take biological repair further than PRP. Where PRP delivers growth factors to stimulate healing, regenerative cell therapy introduces cells that may contribute to new tissue formation and modulation of the joint environment. For knee conditions where the cartilage itself is the problem, not just the inflammatory response around it, this distinction matters clinically.
Recent meta-analyses suggest cautious optimism, but the evidence base requires honest framing. A 2024 systematic review in Osteoarthritis and Cartilage analyzed 16 randomized controlled trials covering 807 patients and found mesenchymal stem cell therapy produced improvements in pain and function compared to controls, with a favorable safety profile. The authors graded the certainty of evidence as low to moderate, meaning the direction of benefit appears consistent but the magnitude and durability remain less certain than for older, better-studied interventions like cortisone or hyaluronic acid.
In practice, this means cell-based therapy is reasonable to consider but should be discussed with realistic expectations. The patients most likely to benefit are those with early-to-moderate knee osteoarthritis, post-meniscectomy or post-injury cases where cartilage degeneration has begun, and patients who have exhausted conservative options but are not yet candidates for replacement.
Cell-based therapies for orthopedic knee conditions are not FDA-approved. Any responsible provider will state this clearly before any procedure. This does not mean they are unproven. It means the regulatory pathway is ongoing and clinical use requires informed consent and realistic expectations.
Provider characteristics influence outcomes in this space. Cell source, processing method, image guidance precision, and physician experience each affect results, which makes provider evaluation part of the decision. One practical distinction worth asking about: whether a clinic operates its own on-site laboratory under clinical supervision, or uses pre-packaged products prepared elsewhere. On-site processing allows for internal cell count and viability testing before a procedure begins, which is a quality control step that is not available when cell products arrive pre-packaged.
How to Think About Sequencing
These options are not mutually exclusive. The more useful question is not which one, but what have you actually tried, in what order, and what did each step tell you about your knee.
A Reasonable Sequence for Most Cases
For most non-acute knee osteoarthritis: start with physical therapy to establish baseline strength and rule out muscular causes. Add hyaluronic acid or limited cortisone if symptoms remain disruptive while pursuing PT. Progress to PRP if conservative care plateaus and imaging shows mild-to-moderate disease. Consider cell-based approaches if PRP has been tried without adequate response, or if the extent of cartilage damage makes a more regenerative approach the appropriate next step.
When Replacement Is the Right Call
Knee replacement is appropriate in certain cases. End-stage bone-on-bone arthritis with mechanical symptoms, severe deformity, and cases that have exhausted reasonable non-operative options are situations where surgery is the right call. Knowing when surgery is appropriate is as important as knowing when it is not, and the patients who do best are usually those who have heard both the surgical and the non-surgical case before deciding.
What Makes Someone a Candidate
Candidacy for knee pain therapy without surgery depends on the specific condition and its severity on imaging, how long symptoms have been present, what has already been tried, body weight and activity level, overall health, and realistic expectations about what non-surgical care can achieve.
The Two-Opinion Rule
The strongest recommendation across every option listed here: get assessments from both an orthopedic surgeon and a regenerative medicine physician. Each will evaluate your case through a different lens, and the contrast between the two opinions is often where the right answer becomes clear. A provider who tells every patient they are a candidate for one specific intervention, or that surgery is the only option, is not giving you individualized care. A good evaluation starts with your imaging and history, acknowledges what you have tried, and is honest about where the evidence is strong and where it is limited.
For Nashville-Area Patients
For patients in Nashville and Franklin, Tennessee who have already worked through standard care without full resolution and want to understand whether a regenerative care plan makes sense for a specific knee condition, Vita Nova Stem Cell Professionals in Franklin offers physician-led evaluations with no obligation to proceed.
Dr. Hemal V. Mehta, MD and Kate Sherman, PA-C review your imaging and history together and give you a clear answer about which paths fit your case and which do not.
Vita Nova Stem Cell Professionals
Phone: (615) 801-8005 | Email: info@vitanovatn.com
Phone Hours: Monday–Friday, 8 AM to 5 PM
Website: vitanovatn.com
DisclaimerThis article is for informational purposes only and does not constitute medical advice. PRP and cell-based therapies for orthopedic knee conditions are not FDA-approved. Individual results vary. Consult a qualified physician before making decisions about care.
Sources
- Bensa A, Previtali D, Sangiorgio A, Boffa A, Salerno M, Filardo G. PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Meta-analysis of Randomized Controlled Trials. American Journal of Sports Medicine. 2025;53(3):745-754.
- McAlindon TE, LaValley MP, Harvey WF, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA. 2017;317(19):1967-1975.
- Sadeghirad B, Rehman Y, Khosravirad A, et al. Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials. Osteoarthritis and Cartilage. 2024;32(10):1207-1219.
- Tian X, Qu Z, Cao Y, Zhang B. Relative efficacy and safety of mesenchymal stem cells for osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology. 2024;15:1366297.
- Oeding JF, Varady NH, Fearington FW, et al. Platelet-Rich Plasma Versus Alternative Injections for Osteoarthritis of the Knee: A Systematic Review and Statistical Fragility Index-Based Meta-analysis of Randomized Controlled Trials. American Journal of Sports Medicine. 2024;52(12):3147-3160.
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology. 2020;72(2):220-233.
- U.S. Food and Drug Administration. FDA regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 21 CFR Part 1271.